Clinical Milestone Payment definition

Clinical Milestone Payment means a one-time payment of $2,500,000 paid by Acquiror to the Exchange Agent upon the latest of (a) administration of the last dose to the last patient in the MPEX-207 Phase 3 Clinical Trial set forth in the Development Plan, (b) January 31, 2012 and (c) two (2) Business Days after the Company has provided Acquiror with evidence of the Stockholder Approval.
Sample 1Sample 2
Clinical Milestone Payment means any payment received by Repligen from any Sublicensee which is payable by reason of the attainment of a clinical objective relating to one or more Licensed Product(s). With respect to each Royalty Quarter, Repligen shall pay to UM [*] of each Clinical Milestone Payment received during such Royalty Quarter.
Sample 1
Clinical Milestone Payment shall have the meaning ascribed thereto in Section 3.1.
Sample 1

Examples of Clinical Milestone Payment in a sentence

  • To the extent not paid pursuant to Section 3.2 of the Option Agreement, a one-time payment of the Clinical Milestone Payment payable in accordance with Section 1.17.

  • ADDITIONAL PAYMENTS 8.1 Clinical Milestone Payment: Licensee shall pay to The Regents [***] within thirty (30) days of the commencement of a clinical [***].

  • Clinical Milestone Payment: Licensee shall pay to The Regents [***] within thirty (30) days of the commencement of the first clinical [***].

  • The DOMINANT OWNER shall before the expiry of the ten (10) year period drill boreholes for water on the DOMINANT TENEMENT.

  • This temporary exception expired on October 1, 2022, after which all sales are sourced pursuant to the general destination sourcing rules.Additional resources The following is a list of statutes, regulations, forms, and guidance pertaining to sales, retail sales, and the sourcing of sales.

  • To the extent not paid pursuant to Section 3.2 of the Option Agreement, Acquiror shall pay the Clinical Milestone Payment to the Exchange Agent (for distribution to the Company Securityholders) upon the later of (i) administration of the last dose to the last patient in the MPEX-207 Phase 3 Clinical Trial set forth in the Development Plan and (ii) January 31, 2012.

  • The processes for both customer and Internal systems have been formulated in a way that there are not a lot of variations.

  • For clarity, if more than one Clinical Milestone Payment in a Region is triggered by the achievement, in such Region, of a non-Clinical Milestone (i.e. the milestones specified in Sections 4.2.4 through 4.2.6, 4.3.4 through 4.3.6, and 4.4.4 through 4.4.6 hereof), then this Section 4.2.10(d)(ii) shall not apply, and all Clinical Milestone Payments so triggered shall be due within thirty (30) days of the triggering event.


More Definitions of Clinical Milestone Payment

Clinical Milestone Payment. Licensee shall pay to The Regents:
Sample 1
Clinical Milestone Payment is defined in Section 11.6.2 (Clinical and Development Milestones).
Sample 1
Clinical Milestone Payment. Licensee shall pay to The Regents [***] within thirty (30) days of the commencement of the first clinical [***]. Additionally, Licensee shall pay to The Regents [***] within thirty (30) days after [***]. The following Paragraph 7.2 and Paragraph 7.3 are added:
Sample 1
Clinical Milestone Payment shall have the meaning set forth in Section 7.3(a). Clinical Development Plan shall have the meaning set forth in Section 3.1(c). CMC stands for chemistry, manufacturing and control and shall mean the industry standard to appropriately manufacture a pharmaceutical or biologic specific manufacturing process, product characteristics, and product testing must be defined in order to ensure that the product is safe, effective and consistent between batches. CMO shall mean a contracting manufacturing organization. COGS stands for Cost of Goods Sold and shall mean [****].
Sample 1

Related to Clinical Milestone Payment

  • Development Milestone Payment shall have the meaning set forth in Section 9.2(a).

  • Milestone Payment means a payment identified in the Implementation Plan to be made following the issue of a Satisfaction Certificate in respect of Achievement of the relevant Milestone;

  • Sales Milestone Payment is defined in Section 5.3.

  • Milestone means an event or task described in the Implementation Plan which, if applicable, must be completed by the relevant Milestone Date;

  • Development Milestone Event has the meaning set forth in Section 7.1.

  • Milestone Event has the meaning set forth in Section 8.4.

  • Milestone Payments has the meaning set forth in Section 4.2.

  • Milestone Events has the meaning set forth in Section 3.3 (Milestone Payments).

  • Milestone 2 means achievement of annual Net Sales of at least $35,000,000 during any Calendar Year ending on or before December 31, 2024.

  • Milestone 1 means achievement of annual Net Sales of at least $20,000,000 during the Calendar Year ending on December 31, 2021.

  • Milestone Payment Date has the meaning set forth in Section 2.4(a).

  • Project Milestone means the project milestone set forth in Schedule-J;

  • Milestones means control points in the project that help to chart progress. Milestones may correspond to the completion of a key deliverable, allowing the next phase of the work to begin. They may also be needed at intermediary points so that, if problems have arisen, corrective measures can be taken. A milestone may be a critical decision point in the project where, for example, the consortium must decide which of several technologies to adopt for further development.

  • Project Milestones means the project milestones set forth in Schedule-G;

  • Milestone Date means the date set against the relevant Milestone in the Implementation Plan;

  • Milestone Dates means the dates for completion of specified Project activities as contained in the Project Schedule.

  • Performance Milestone means an act or event specified in section 5.1 and described in section 9 of the EPLA.

  • Milestone Schedule means Seller’s milestone schedule, the form of which is attached to this Agreement as Exhibit Q.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase III Clinical Study means a human clinical study of a product on a sufficient number of subjects that is designed to establish that such product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is intended to support Regulatory Approval of such product, as described in 21 C.F.R. 312.21(c). 1.185. [***] 1.186. [***]

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Phase I Clinical Trial means a clinical trial conducted in healthy humans or patients, which clinical trial is designed to establish the safety, drug-drug interactions and/or pharmacokinetics of an investigational drug given its intended use, and to support continued testing of such drug in Phase II Clinical Trials.

  • Initial Indication means the use of a Product for the treatment of opioid addiction.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase III Clinical Trial means a human clinical trial, the principal purpose of which is to demonstrate clinically and statistically the efficacy and safety of a Licensed Product for one or more indications in order to obtain Marketing Approval of such Licensed Product for such indication(s), as further defined in 21 C.F.R. §312.21 or a similar clinical study in a country other than the United States.